Eleven Biotherapeutics looks to raise almost $70M in IPO

Eleven Biotherapeutics has filed to raise up to $69M in an IPO on Nasdaq, where it will trade under the EBIO ticker symbol.

Eleven Biotherapeutics develops a protein engineering platform called AMP-Rx for use in treating eye diseases.

The company was founded in 2008 and earned $1M in collaboration revenue in the year through September.


Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs